

Philip M Sedgwick

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1849182/publications.pdf>

Version: 2024-02-01

310
papers

7,025
citations

76031

42
h-index

93651

72
g-index

329
all docs

329
docs citations

329
times ranked

10812
citing authors

#	ARTICLE	IF	CITATIONS
1	Preoperative Factors Affecting the Patient-Reported Outcome Measures following Total Knee Replacement: Socioeconomic Factors and Preoperative OKS Have a Clinically Meaningful Effect. <i>Journal of Knee Surgery</i> , 2022, 35, 940-948.	0.9	2
2	Outcome reporting in randomized controlled trials (RCTs) on the pharmacological management of idiopathic overactive bladder (OAB) in women; a systematic review for the development of core outcome sets (COS). <i>International Urogynecology Journal</i> , 2022, 33, 1243-1250.	0.7	1
3	Influence of previous delivery mode on perineal trauma risk. <i>International Journal of Gynecology and Obstetrics</i> , 2022, 159, 757-763.	1.0	2
4	Current controversies: Null hypothesis significance testing. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2022, 101, 624-627.	1.3	16
5	Prevalence, severity, and risk factors of disability among adults living with HIV accessing routine outpatient HIV care in London, United Kingdom (UK): A cross-sectional self-report study. <i>PLoS ONE</i> , 2022, 17, e0267271.	1.1	1
6	P193â€fHow did people with rheumatoid arthritis experience the COVID-19 pandemic? Interim qualitative results from the BIORA-PAIN study. <i>Rheumatology</i> , 2022, 61, .	0.9	0
7	Defining the Mean Angle of Diaphyseal Long Bone Nonunionsâ€”Does Shear Prevail?. <i>Journal of Orthopaedic Trauma</i> , 2021, 35, e322-e327.	0.7	4
8	Theatre efficiency in COVID-19 pandemic conditions: The collaborative experience of four level 1 major trauma centres in the UK. <i>Bone & Joint Open</i> , 2021, 2, 886-892.	1.1	2
9	Prostaglandin insert dinoprostone versus trans-cervical balloon catheter for outpatient labour induction: a randomised controlled trial of feasibility (PROBIT-F). <i>Pilot and Feasibility Studies</i> , 2020, 6, 113.	0.5	6
10	40 days and 40 nights: Clinical characteristics of major trauma and orthopaedic injury comparing the incubation and lockdown phases of COVID-19 infection. <i>Bone & Joint Open</i> , 2020, 1, 330-338.	1.1	2
11	Erythrocyte Encapsulated Thymidine Phosphorylase for the Treatment of Patients with Mitochondrial Neurogastrointestinal Encephalomyopathy: Study Protocol for a Multi-Centre, Multiple Dose, Open Label Trial. <i>Journal of Clinical Medicine</i> , 2019, 8, 1096.	1.0	39
12	Results from an online survey of adults with cystic fibrosis: Accessing and using life expectancy information. <i>PLoS ONE</i> , 2019, 14, e0213639.	1.1	12
13	A comparative study of obstetric anal sphincter injuries in vaginal deliveries of twins and singleton pregnancies. <i>Neurourology and Urodynamics</i> , 2018, 37, 2717-2723.	0.8	0
14	Arterial versus venous lactate: a measure of sepsis in children. <i>European Journal of Pediatrics</i> , 2017, 176, 1055-1060.	1.3	25
15	Laser treatment for female facial hirsutism: are quality-of-life benefits sustainable?. <i>Clinical and Experimental Dermatology</i> , 2016, 41, 248-252.	0.6	62
16	Controlled trials: allocation concealment, random allocation, and blinding. <i>BMJ, The</i> , 2015, 350, h2633-h2633.	3.0	8
17	Measuring the detriment of treatment: number needed to harm. <i>BMJ, The</i> , 2015, 350, h2763-h2763.	3.0	4
18	What are the risks?. <i>BMJ, The</i> , 2015, 350, h2931-h2931.	3.0	2

#	ARTICLE	IF	CITATIONS
19	Uncertainty in sample estimates: standard error. BMJ, The, 2015, 350, h3078-h3078.	3.0	1
20	Bias in observational study designs: case-control studies. BMJ, The, 2015, 350, h560-h560.	3.0	19
21	Intention to treat analysis versus per protocol analysis of trial data. BMJ, The, 2015, 350, h681-h681.	3.0	68
22	Quantifying treatment effects in randomised controlled trials. BMJ, The, 2015, 350, h420-h420.	3.0	1
23	Meta-analysis: testing for reporting bias. BMJ, The, 2015, 350, g7857-g7857.	3.0	18
24	Clinical trials: outcome measures. BMJ, The, 2015, 350, h121-h121.	3.0	7
25	Treatment effects and placebo effects. BMJ, The, 2015, 350, h267-h267.	3.0	16
26	Confidence intervals, P values, and statistical significance. BMJ, The, 2015, 350, h1113-h1113.	3.0	11
27	Standard deviation or the standard error of the mean. BMJ, The, 2015, 350, h831-h831.	3.0	7
28	Bias in observational study designs: cross sectional studies. BMJ, The, 2015, 350, h1286-h1286.	3.0	74
29	Treatment allocation in trials: stratified randomisation. BMJ, The, 2015, 350, h978-h978.	3.0	9
30	How to read a forest plot in a meta-analysis:. BMJ, The, 2015, 351, h4028.	3.0	35
31	What is significance?. BMJ, The, 2015, 350, h3475-h3475.	3.0	2
32	A comparison of sampling error and standard error. BMJ, The, 2015, 351, h3577.	3.0	4
33	Bias in experimental study designs: randomised controlled trials with parallel groups. BMJ, The, 2015, 351, h3869.	3.0	8
34	Placebos and sham treatments. BMJ, The, 2015, 351, h3755.	3.0	9
35	Randomised controlled trials: understanding power. BMJ, The, 2015, 350, h3229-h3229.	3.0	1
36	Measuring the benefit of treatment: number needed to treat. BMJ, The, 2015, 350, h2206-h2206.	3.0	8

#	ARTICLE	IF	CITATIONS
37	A comparison of parametric and non-parametric statistical tests. BMJ, The, 2015, 350, h2053-h2053.	3.0	23
38	How to read a receiver operating characteristic curve. BMJ, The, 2015, 350, h2464-h2464.	3.0	11
39	What are the odds?. BMJ, The, 2015, 350, h2327-h2327.	3.0	2
40	Randomised controlled trials: the importance of sample size. BMJ, The, 2015, 350, h1586-h1586.	3.0	5
41	Randomised controlled trials: understanding effect sizes. BMJ, The, 2015, 350, h1690-h1690.	3.0	13
42	Meta-analyses: what is heterogeneity?. BMJ, The, 2015, 350, h1435-h1435.	3.0	131
43	Evaluating the performance of a screening test for depression in primary care. BMJ, The, 2015, 350, h1801-h1801.	3.0	2
44	Uncertainty in sample estimates: sampling error. BMJ, The, 2015, 350, h1914-h1914.	3.0	4
45	Understanding the ecological fallacy. BMJ, The, 2015, 351, h4773.	3.0	71
46	Randomised controlled trials: understanding confounding. BMJ, The, 2015, 351, h5119.	3.0	9
47	Multistage sampling. BMJ, The, 2015, 351, h4155.	3.0	34
48	Bias in randomised controlled trials: comparison of crossover group and parallel group designs. BMJ, The, 2015, 351, h4283.	3.0	12
49	Units of sampling, observation, and analysis. BMJ, The, 2015, 351, h5396.	3.0	3
50	Interpreting hazard ratios. BMJ, The, 2015, 351, h4631.	3.0	15
51	What is publication bias in a meta-analysis?. BMJ, The, 2015, 351, h4419.	3.0	54
52	Understanding the Hawthorne effect. BMJ, The, 2015, 351, h4672.	3.0	430
53	How to read a funnel plot in a meta-analysis. BMJ, The, 2015, 351, h4718.	3.0	167
54	Spearman's rank correlation coefficient. BMJ, The, 2014, 349, g7528-g7528.	3.0	4

#	ARTICLE	IF	CITATIONS
55	Do Blood Pressure Levels and Other Patient Characteristics Influence Native Fistula Patency?. Seminars in Dialysis, 2014, 27, E27-31.	0.7	8
56	One way analysis of variance: post hoc testing. BMJ, The, 2014, 349, g7067-g7067.	3.0	6
57	Spearman's rank correlation coefficient. BMJ: British Medical Journal, 2014, 349, g7327.	2.4	146
58	Randomised controlled trials: subgroup analyses. BMJ, The, 2014, 349, g7513-g7513.	3.0	7
59	Bias in observational study designs: prospective cohort studies. BMJ, The, 2014, 349, g7731-g7731.	3.0	43
60	Randomised controlled trials: tests of interaction. BMJ, The, 2014, 349, g6820-g6820.	3.0	1
61	Explanatory trials versus pragmatic trials. BMJ, The, 2014, 349, g6694-g6694.	3.0	61
62	Sample size: how many participants are needed in a cohort study?. BMJ, The, 2014, 349, g6557-g6557.	3.0	6
63	Clinical trials: units of randomisation. BMJ, The, 2014, 348, g3297-g3297.	3.0	5
64	Clinical significance versus statistical significance. BMJ, The, 2014, 348, g2130-g2130.	3.0	33
65	What is a factorial study design?. BMJ, The, 2014, 349, g5455-g5455.	3.0	6
66	Randomised controlled trials: "within subject" versus "between subject" designs. BMJ, The, 2014, 347, g6435-g6435.	3.0	5
67	Poisson regression. BMJ, The, 2014, 349, g6150-g6150.	3.0	4
68	Standardising outcome measures using z scores. BMJ, The, 2014, 349, g5878-g5878.	3.0	11
69	Understanding confidence intervals. BMJ, The, 2014, 349, g6051-g6051.	3.0	11
70	Multiple hypothesis testing and Bonferroni's correction. BMJ, The, 2014, 349, g6284-g6284.	3.0	109
71	Understanding why "absence of evidence is not evidence of absence". BMJ, The, 2014, 349, g4751-g4751.	3.0	9
72	What is a non-randomised controlled trial?. BMJ, The, 2014, 348, g4115-g4115.	3.0	20

#	ARTICLE	IF	CITATIONS
73	Randomised controlled trials: inferring significance of treatment effects based on confidence intervals. BMJ, The, 2014, 349, g5196-g5196.	3.0	6
74	What is a crossover trial?. BMJ, The, 2014, 348, g3191-g3191.	3.0	27
75	Pitfalls of statistical hypothesis testing: multiple testing. BMJ, The, 2014, 349, g5310-g5310.	3.0	14
76	What are randomised consent designs?. BMJ, The, 2014, 349, g4727-g4727.	3.0	1
77	Before and after study designs. BMJ, The, 2014, 349, g5074-g5074.	3.0	60
78	Measuring the performance of screening tests. BMJ, The, 2014, 348, g4438-g4438.	3.0	1
79	Randomised controlled trials: missing data. BMJ, The, 2014, 349, g4656-g4656.	3.0	13
80	Pitfalls of statistical hypothesis testing: type I and type II errors. BMJ, The, 2014, 349, g4287-g4287.	3.0	24
81	Understanding P values. BMJ, The, 2014, 349, g4550-g4550.	3.0	9
82	Understanding statistical hypothesis testing. BMJ, The, 2014, 348, g3557-g3557.	3.0	21
83	Unit of observation versus unit of analysis. BMJ, The, 2014, 348, g3840-g3840.	3.0	12
84	Ecological studies: advantages and disadvantages. BMJ, The, 2014, 348, g2979-g2979.	3.0	139
85	What is an open label trial?. BMJ, The, 2014, 348, g3434-g3434.	3.0	11
86	What are the four phases of clinical research trials?. BMJ, The, 2014, 348, g3727-g3727.	3.0	14
87	Non-response bias versus response bias. BMJ, The, 2014, 348, g2573-g2573.	3.0	71
88	Non-parametric statistical tests for two independent groups: numerical data. BMJ, The, 2014, 348, g2907-g2907.	3.0	5
89	Randomised controlled trials: evaluating and communicating treatment effects. BMJ, The, 2014, 348, g1905-g1905.	3.0	1
90	Treatment allocation in trials: cluster randomisation. BMJ, The, 2014, 348, g2820-g2820.	3.0	5

#	ARTICLE	IF	CITATIONS
91	Treatment allocation in trials: block randomisation. <i>BMJ, The</i> , 2014, 348, g2409-g2409.	3.0	8
92	Randomised controlled trials: internal versus external validity. <i>BMJ, The</i> , 2014, 348, g1742-g1742.	3.0	12
93	Prognostic scores. <i>BMJ, The</i> , 2014, 348, g282-g282.	3.0	0
94	Cluster sampling. <i>BMJ, The</i> , 2014, 348, g1215-g1215.	3.0	15
95	Nested case-control studies: advantages and disadvantages. <i>BMJ, The</i> , 2014, 348, g1532-g1532.	3.0	27
96	Case-control studies: advantages and disadvantages. <i>BMJ, The</i> , 2014, 348, f7707-f7707.	3.0	26
97	Retrospective cohort studies: advantages and disadvantages. <i>BMJ, The</i> , 2014, 348, g1072-g1072.	3.0	93
98	Relative risks versus odds ratios. <i>BMJ, The</i> , 2014, 348, g1407-g1407.	3.0	32
99	What is an "n-of-1" trial?. <i>BMJ, The</i> , 2014, 348, g2674-g2674.	3.0	11
100	Placebo controlled trials. <i>BMJ, The</i> , 2014, 348, g1635-g1635.	3.0	4
101	Parametric statistical tests for two related groups: numerical data. <i>BMJ, The</i> , 2014, 348, g124-g124.	3.0	2
102	Evidence of mycobacterial disease in COPD patients with lung volume reduction surgery; the importance of histological assessment of specimens: a cohort study. <i>BMC Pulmonary Medicine</i> , 2014, 14, 124.	0.8	27
103	Cross sectional studies: advantages and disadvantages. <i>BMJ, The</i> , 2014, 348, g2276-g2276.	3.0	187
104	How to read a Kaplan-Meier survival plot. <i>BMJ, The</i> , 2014, 349, g5608-g5608.	3.0	14
105	Randomised controlled trials: balance in baseline characteristics. <i>BMJ, The</i> , 2014, 349, g5721-g5721.	3.0	12
106	Development and evaluation of a risk communication curriculum for medical students. <i>Patient Education and Counseling</i> , 2014, 94, 43-49.	1.0	43
107	Meta-analyses: heterogeneity and subgroup analysis. <i>BMJ, The</i> , 2013, 346, f4040-f4040.	3.0	100
108	Open label crossover trials. <i>BMJ, The</i> , 2013, 346, f4186-f4186.	3.0	2

#	ARTICLE	IF	CITATIONS
109	Analysing case-control studies: adjusting for confounding. BMJ, The, 2013, 346, f25-f25.	3.0	8
110	Sample size: how many participants are needed in a trial?. BMJ, The, 2013, 346, f1041-f1041.	3.0	10
111	Normal ranges. BMJ, The, 2013, 346, f1343-f1343.	3.0	1
112	Limits of agreement (Bland-Altman method). BMJ, The, 2013, 346, f1630-f1630.	3.0	63
113	Case-control studies: measures of risk. BMJ, The, 2013, 346, f1185-f1185.	3.0	9
114	Meta-analyses: how to read a funnel plot. BMJ, The, 2013, 346, f1342-f1342.	3.0	104
115	Units of analysis. BMJ, The, 2013, 346, f2128-f2128.	3.0	0
116	Variables, sample estimates, and population parameters. BMJ, The, 2013, 346, f2019-f2019.	3.0	0
117	Correlation versus linear regression. BMJ, The, 2013, 346, f2686-f2686.	3.0	6
118	Receiver operating characteristic curves. BMJ, The, 2013, 346, f2493-f2493.	3.0	12
119	Cluster randomised controlled trials: sample size calculations. BMJ, The, 2013, 346, f2839-f2839.	3.0	14
120	What is per protocol analysis?. BMJ, The, 2013, 346, f3748-f3748.	3.0	9
121	P values or confidence intervals?. BMJ, The, 2013, 346, f3212-f3212.	3.0	6
122	Analysis of longitudinal studies. BMJ, The, 2013, 346, f363-f363.	3.0	1
123	Selection bias versus allocation bias. BMJ, The, 2013, 346, f3345-f3345.	3.0	21
124	Generalisation and extrapolation of study results. BMJ, The, 2013, 346, f3022-f3022.	3.0	2
125	Double dummy trials incorporating factorial designs. BMJ, The, 2013, 346, f3539-f3539.	3.0	0
126	What is intention to treat analysis?. BMJ, The, 2013, 346, f3662-f3662.	3.0	11

#	ARTICLE	IF	CITATIONS
127	What is the standard error of the mean?. BMJ, The, 2013, 346, f532-f532.	3.0	0
128	Convenience sampling. BMJ, The, 2013, 347, f6304-f6304.	3.0	111
129	Snowball sampling. BMJ, The, 2013, 347, f7511-f7511.	3.0	57
130	What is a non-inferiority trial?. BMJ, The, 2013, 347, f6853-f6853.	3.0	6
131	Meta-analyses: standardised mean differences. BMJ, The, 2013, 347, f7257-f7257.	3.0	43
132	Kaplan-Meier survival curves: interpretation and communication of risk. BMJ, The, 2013, 347, f7118-f7118.	3.0	8
133	The importance of statistical power. BMJ, The, 2013, 347, f6282-f6282.	3.0	12
134	Prospective cohort studies: advantages and disadvantages. BMJ, The, 2013, 347, f6726-f6726.	3.0	38
135	Stratified cluster sampling. BMJ, The, 2013, 347, f7016-f7016.	3.0	24
136	Treatment allocation by minimisation. BMJ, The, 2013, 347, f6569-f6569.	3.0	1
137	The nocebo effect. BMJ, The, 2013, 347, f6130-f6130.	3.0	2
138	What is a patient preference trial?. BMJ, The, 2013, 347, f5970-f5970.	3.0	9
139	Sham treatments. BMJ, The, 2013, 347, f5819-f5819.	3.0	3
140	Cox proportional hazards regression. BMJ, The, 2013, 347, f4919-f4919.	3.0	10
141	Odds and odds ratios. BMJ, The, 2013, 347, f5067-f5067.	3.0	7
142	Kaplan-Meier survival analysis: types of censored observations. BMJ, The, 2013, 347, f4663-f4663.	3.0	2
143	What is number needed to treat (NNT)?. BMJ, The, 2013, 347, f4605-f4605.	3.0	7
144	What is number needed to harm (NNH)?. BMJ, The, 2013, 347, f4869-f4869.	3.0	11

#	ARTICLE	IF	CITATIONS
145	What is a superiority trial?. BMJ, The, 2013, 347, f5420-f5420.	3.0	13
146	Intraclass correlation coefficient. BMJ, The, 2013, 346, f1816-f1816.	3.0	9
147	Stratified random allocation. BMJ, The, 2013, 346, f822-f822.	3.0	4
148	The purpose of control groups. BMJ, The, 2013, 346, f658-f658.	3.0	0
149	Questionnaire surveys: sources of bias. BMJ, The, 2013, 347, f5265-f5265.	3.0	53
150	Equivalence trials. BMJ, The, 2013, 346, f184-f184.	3.0	5
151	Observational study design. BMJ, The, 2012, 345, e5856-e5856.	3.0	2
152	Confidence intervals and statistical significance. BMJ: British Medical Journal, 2012, 344, e2238-e2238.	2.4	6
153	Variability in the Treatment of Acute Spinal Cord Injury in the United Kingdom: Results of a National Survey. Journal of Neurotrauma, 2012, 29, 880-888.	1.7	50
154	Observational study designs. BMJ, The, 2012, 344, e4209-e4209.	3.0	0
155	Allocation concealment. BMJ: British Medical Journal, 2012, 344, e156-e156.	2.4	4
156	Non-parametric statistical tests for two related groups: numerical data. BMJ, The, 2012, 344, e2537-e2537.	3.0	6
157	What is recall bias?. BMJ, The, 2012, 344, e3519-e3519.	3.0	45
158	Placebo run in periods. BMJ, The, 2012, 344, e3827-e3827.	3.0	2
159	Standardisation of outcome measures (z scores). BMJ, The, 2012, 345, e6178-e6178.	3.0	3
160	"n of 1" trials. BMJ: British Medical Journal, 2012, 344, e844-e844.	2.4	2
161	External and internal validity in clinical trials. BMJ: British Medical Journal, 2012, 344, e1004-e1004.	2.4	13
162	Statistical tests for independent groups: categorical data. BMJ: British Medical Journal, 2012, 344, e344-e344.	2.4	11

#	ARTICLE	IF	CITATIONS
163	Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anaemia Working Party. <i>Blood</i> , 2012, 119, 5391-5396.	0.6	156
164	What is a P value?. <i>BMJ, The</i> , 2012, 345, e7767-e7767.	3.0	7
165	Confounding in clinical trials. <i>BMJ, The</i> , 2012, 345, e7951-e7951.	3.0	10
166	Skewed distributions. <i>BMJ, The</i> , 2012, 345, e7534-e7534.	3.0	1
167	How to read a forest plot. <i>BMJ, The</i> , 2012, 345, e8335-e8335.	3.0	11
168	Crossover trials. <i>BMJ, The</i> , 2012, 344, e3710-e3710.	3.0	4
169	Cohen's coefficient \hat{A} . <i>BMJ: British Medical Journal</i> , 2012, 344, e1178-e1178.	2.4	6
170	Incidence rates. <i>BMJ: British Medical Journal</i> , 2012, 344, e1589-e1589.	2.4	6
171	One way analysis of variance. <i>BMJ, The</i> , 2012, 344, e2427-e2427.	3.0	5
172	Restricted randomisation. <i>BMJ: British Medical Journal</i> , 2012, 344, e1324-e1324.	2.4	4
173	Why match in case-control studies?. <i>BMJ: British Medical Journal</i> , 2012, 344, e691-e691.	2.4	6
174	Parametric v non-parametric statistical tests. <i>BMJ: British Medical Journal</i> , 2012, 344, e1753-e1753.	2.4	21
175	Analysis of outcome measures within treatment groups. <i>BMJ, The</i> , 2012, 345, e7201-e7201.	3.0	1
176	Estimating the population at risk. <i>BMJ, The</i> , 2012, 345, e6859-e6859.	3.0	9
177	What is risk?. <i>BMJ, The</i> , 2012, 345, e7036-e7036.	3.0	1
178	Meta-analyses: tests of heterogeneity. <i>BMJ, The</i> , 2012, 344, e3971-e3971.	3.0	12
179	Multiple significance tests: the Bonferroni correction. <i>BMJ: British Medical Journal</i> , 2012, 344, e509-e509.	2.4	124
180	The healthy entrant effect. <i>BMJ, The</i> , 2012, 344, e2728-e2728.	3.0	3

#	ARTICLE	IF	CITATIONS
181	Sequential trials. BMJ: British Medical Journal, 2012, 344, e2102-e2102.	2.4	0
182	Zelen's design. BMJ, The, 2012, 345, e8505-e8505.	3.0	0
183	Effect sizes. BMJ, The, 2012, 345, e7370-e7370.	3.0	8
184	Why randomise in clinical trials?. BMJ, The, 2012, 345, e5584-e5584.	3.0	7
185	Proportional quota sampling. BMJ, The, 2012, 345, e6336-e6336.	3.0	20
186	The normal distribution. BMJ, The, 2012, 345, e6533-e6533.	3.0	6
187	Log transformation of data. BMJ, The, 2012, 345, e6727-e6727.	3.0	21
188	Is there an association between adolescent females' skin tone and behaviour regarding sun exposure?. Bone, 2012, 50, S176.	1.4	0
189	Hazards and hazard ratios. BMJ, The, 2012, 345, e5980-e5980.	3.0	9
190	Absolute and relative risks. BMJ, The, 2012, 345, e5613-e5613.	3.0	7
191	Parametric statistical tests for independent groups: numerical data. BMJ, The, 2012, 345, e8145-e8145.	3.0	1
192	Open clinical trials. BMJ, The, 2012, 345, e4749-e4749.	3.0	1
193	Confidence intervals: predicting uncertainty. BMJ, The, 2012, 344, e3147-e3147.	3.0	5
194	Non-parametric statistical tests for independent groups: numerical data. BMJ, The, 2012, 344, e3354-e3354.	3.0	6
195	What are odds?. BMJ, The, 2012, 344, e2853-e2853.	3.0	3
196	Populations and samples. BMJ, The, 2012, 344, e3048-e3048.	3.0	0
197	Confidence intervals and statistical significance: rules of thumb. BMJ, The, 2012, 345, e4960-e4960.	3.0	16
198	Randomised controlled trials with full factorial designs. BMJ, The, 2012, 345, e5114-e5114.	3.0	2

#	ARTICLE	IF	CITATIONS
199	Statistical tests for independent groups: time to event data. BMJ, The, 2012, 345, e5257-e5257.	3.0	0
200	What is sampling error?. BMJ, The, 2012, 344, e4285-e4285.	3.0	15
201	Pearson's correlation coefficient. BMJ, The, 2012, 345, e4483-e4483.	3.0	358
202	Cluster randomised controlled trials. BMJ, The, 2012, 345, e4654-e4654.	3.0	14
203	Standard deviation versus standard error. BMJ: British Medical Journal, 2011, 343, d8010-d8010.	2.4	9
204	The Hawthorne effect. BMJ: British Medical Journal, 2011, 344, d8262-d8262.	2.4	34
205	Odds ratios and adjusting for confounding. BMJ: British Medical Journal, 2011, 343, d6833-d6833.	2.4	2
206	Hazard ratios. BMJ: British Medical Journal, 2011, 343, d5918-d5918.	2.4	5
207	Cohort studies: sources of bias. BMJ: British Medical Journal, 2011, 343, d7839-d7839.	2.4	2
208	Screening tests: likelihood ratios. BMJ: British Medical Journal, 2011, 342, d3986-d3986.	2.4	3
209	Random sampling versus random allocation. BMJ: British Medical Journal, 2011, 343, d7453-d7453.	2.4	5
210	Control treatments. BMJ: British Medical Journal, 2011, 342, d2109-d2109.	2.4	0
211	Analysis by per protocol. BMJ: British Medical Journal, 2011, 342, d2330-d2330.	2.4	5
212	Number needed to treat I. BMJ: British Medical Journal, 2011, 342, d2463-d2463.	2.4	4
213	Number needed to treat II. BMJ: British Medical Journal, 2011, 342, d2664-d2664.	2.4	2
214	Number needed to harm. BMJ: British Medical Journal, 2011, 342, d2811-d2811.	2.4	3
215	Superiority trials. BMJ: British Medical Journal, 2011, 342, d2981-d2981.	2.4	4
216	Non-inferiority trials. BMJ: British Medical Journal, 2011, 342, d3253-d3253.	2.4	2

#	ARTICLE	IF	CITATIONS
217	Open label trials. BMJ: British Medical Journal, 2011, 342, d3427-d3427.	2.4	0
218	Patient preference trials. BMJ: British Medical Journal, 2011, 342, d3602-d3602.	2.4	0
219	Screening tests: indices of performance. BMJ: British Medical Journal, 2011, 342, d3763-d3763.	2.4	1
220	Receiver operating characteristic curves. BMJ, The, 2011, 343, d4302-d4302.	3.0	4
221	The ecological fallacy. BMJ: British Medical Journal, 2011, 343, d4670-d4670.	2.4	14
222	Survival (time to event) data: censored observations. BMJ: British Medical Journal, 2011, 343, d4816-d4816.	2.4	6
223	Meta-analyses: sources of bias. BMJ: British Medical Journal, 2011, 343, d5085-d5085.	2.4	0
224	Meta-analyses: funnel plots. BMJ: British Medical Journal, 2011, 343, d5372-d5372.	2.4	6
225	Sample size and power. BMJ: British Medical Journal, 2011, 343, d5579-d5579.	2.4	2
226	Non-randomised studies. BMJ: British Medical Journal, 2011, 343, d5741-d5741.	2.4	2
227	Phases of clinical trials. BMJ: British Medical Journal, 2011, 343, d6068-d6068.	2.4	12
228	Case-control studies: sources of bias. BMJ: British Medical Journal, 2011, 343, d6284-d6284.	2.4	3
229	Screening tests and indices of performance: effects of prevalence. BMJ: British Medical Journal, 2011, 343, d6483-d6483.	2.4	2
230	Derivation of hazard ratios. BMJ: British Medical Journal, 2011, 343, d6994-d6994.	2.4	3
231	Block randomisation. BMJ: British Medical Journal, 2011, 343, d7139-d7139.	2.4	7
232	Double dummy trials. BMJ: British Medical Journal, 2011, 343, d7294-d7294.	2.4	5
233	The placebo effect. BMJ, The, 2011, 343, d7665-d7665.	3.0	3
234	Analysis by intention to treat. BMJ: British Medical Journal, 2011, 342, d2212-d2212.	2.4	9

#	ARTICLE	IF	CITATIONS
235	Bias in clinical trials. BMJ: British Medical Journal, 2011, 343, d4176-d4176.	2.4	14
236	Meta-analyses II. BMJ: British Medical Journal, 2011, 341, d229-d229.	2.4	3
237	Meta-analyses I. BMJ: British Medical Journal, 2011, 342, d45-d45.	2.4	4
238	Meta-analyses IV. BMJ: British Medical Journal, 2011, 342, d540-d540.	2.4	1
239	Meta-analyses V. BMJ: British Medical Journal, 2011, 342, d686-d686.	2.4	1
240	Meta-analyses VII. BMJ: British Medical Journal, 2011, 342, d1108-d1108.	2.4	0
241	Meta-analyses VI. BMJ: British Medical Journal, 2011, 342, d937-d937.	2.4	0
242	Sampling methods III. BMJ: British Medical Journal, 2011, 342, d1537-d1537.	2.4	0
243	Sampling methods I. BMJ: British Medical Journal, 2011, 342, d1249-d1249.	2.4	3
244	Sampling methods II. BMJ: British Medical Journal, 2011, 342, d1387-d1387.	2.4	0
245	Observational Study Design I. BMJ: British Medical Journal, 2011, 342, d1742-d1742.	2.4	0
246	Prospective Phase II Pilot Study of Rabbit Antithymocyte Globulin (ATG, Thymoglobuline) with Ciclosporin for Patients with Acquired Aplastic Anemia and Matched Pair Analysis with Patients Treated with Horse ATG (Lymphoglobuline) and Ciclosporin: A Study From the EBMT Severe Aplastic Anemia Working Party (RATGAA07). Blood, 2011, 118, 2408-2408.	0.6	1
247	Relative risks and statistical significance. BMJ: British Medical Journal, 2010, 341, c4265-c4265.	2.4	2
248	Per protocol analysis. BMJ: British Medical Journal, 2010, 340, c1825-c1825.	2.4	9
249	Nested case-control studies. BMJ: British Medical Journal, 2010, 340, c2582-c2582.	2.4	11
250	Odds ratios. BMJ: British Medical Journal, 2010, 341, c4414-c4414.	2.4	12
251	Confounding in randomised controlled trials. BMJ: British Medical Journal, 2010, 341, c5403-c5403.	2.4	3
252	Cross sectional studies. BMJ: British Medical Journal, 2010, 340, c846-c846.	2.4	4

#	ARTICLE	IF	CITATIONS
253	Sampling II. BMJ: British Medical Journal, 2010, 340, b5677-b5677.	2.4	0
254	Placebos. BMJ: British Medical Journal, 2010, 340, c247-c247.	2.4	0
255	Control groups. BMJ: British Medical Journal, 2010, 340, c391-c391.	2.4	0
256	Sampling III. BMJ: British Medical Journal, 2010, 340, c93-c93.	2.4	1
257	Generalisation and extrapolation. BMJ: British Medical Journal, 2010, 340, c717-c717.	2.4	2
258	Standard error of the mean. BMJ: British Medical Journal, 2010, 340, c1437-c1437.	2.4	5
259	Internal and external validity. BMJ: British Medical Journal, 2010, 340, c1705-c1705.	2.4	2
260	Variables and parameters. BMJ: British Medical Journal, 2010, 340, c1568-c1568.	2.4	3
261	Sample size calculations I. BMJ: British Medical Journal, 2010, 340, c3104-c3104.	2.4	3
262	Sample size calculations II. BMJ: British Medical Journal, 2010, 340, c3299-c3299.	2.4	1
263	The log rank test. BMJ: British Medical Journal, 2010, 341, c3773-c3773.	2.4	2
264	Hazard ratios. BMJ: British Medical Journal, 2010, 341, c4566-c4566.	2.4	0
265	Relative risks and confidence intervals. BMJ: British Medical Journal, 2010, 341, c4166-c4166.	2.4	2
266	Prevalence and incidence. BMJ: British Medical Journal, 2010, 341, c4709-c4709.	2.4	14
267	Consultation activities of clinical ethics committees in the United Kingdom: an empirical study and wake-up call. Postgraduate Medical Journal, 2009, 85, 451-454.	0.9	24
268	Assessment of risk communication by objective structured clinical examination. Medical Education, 2009, 43, 484-484.	1.1	4
269	Sampling I. BMJ: British Medical Journal, 2009, 339, b5512-b5512.	2.4	3
270	Screening tests. BMJ: British Medical Journal, 2009, 339, b3941-b3941.	2.4	0

#	ARTICLE	IF	CITATIONS
271	Screening tests III. BMJ: British Medical Journal, 2009, 339, b4247-b4247.	2.4	0
272	Screening tests II. BMJ: British Medical Journal, 2009, 339, b4030-b4030.	2.4	0
273	Screening tests IV. BMJ: British Medical Journal, 2009, 339, b4365-b4365.	2.4	0
274	Case-control studies. BMJ: British Medical Journal, 2009, 339, b4135-b4135.	2.4	5
275	Study design. BMJ: British Medical Journal, 2009, 339, b4458-b4458.	2.4	0
276	Random allocation III. BMJ: British Medical Journal, 2009, 339, b5072-b5072.	2.4	0
277	Hippocampal FGF-2 and FGFR1 mRNA expression in major depression, schizophrenia and bipolar disorder. Brain Research Bulletin, 2006, 70, 221-227.	1.4	152
278	Student attitudes towards anatomy teaching and learning in a multiprofessional context. Medical Education, 2004, 38, 737-748.	1.1	49
279	Anxiety in medical students: is preparation for full-time clinical attachments more dependent upon differences in maturity or on educational programmes for undergraduate and graduate entry students?. Medical Education, 2004, 38, 1154-1163.	1.1	66
280	Teaching medical students and doctors how to communicate risk. BMJ: British Medical Journal, 2003, 327, 694-695.	2.4	70
281	Impact of patient suicide on psychiatric trainees. Psychiatric Bulletin, 2002, 26, 53-55.	0.3	41
282	Relatives of patients with severe psychotic disorders: Factors that influence contact frequency. British Journal of Psychiatry, 2001, 178, 248-254.	1.7	25
283	Improving the delivery of analgesia to children in pain. Emergency Medicine Journal, 2001, 18, 159-161.	0.4	38
284	Is there a dissociative process in sleepwalking and night terrors?. Postgraduate Medical Journal, 2001, 77, 244-249.	0.9	58
285	Selenium supplementation and selenoenzyme activity. Clinical Science, 2000, 99, 579-581.	1.8	8
286	Drug use, self report and urinalysis. Drug and Alcohol Dependence, 2000, 58, 111-116.	1.6	44
287	Bereavement and grief in adults with learning disabilities. British Journal of Psychiatry, 1999, 175, 348-350.	1.7	62
288	Changes in Plasma Concentrations of Leptin and Body Fat Composition during Weight Restoration in Anorexia Nervosa. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 2257-2257.	1.8	10

#	ARTICLE	IF	CITATIONS
289	Pulmonary tuberculosis: radiological features in west Africans coinfectd with HIV.. British Journal of Radiology, 1999, 72, 339-344.	1.0	29
290	Fragile-X syndrome, Down's syndrome and autism: awareness and knowledge amongst special educators. Journal of Intellectual Disability Research, 1999, 43, 314-324.	1.2	24
291	Incidence and demographic correlates of eating disorder symptoms in a pregnant population. , 1999, 26, 448-452.		31
292	Why may teenage girls persist in smoking?. Journal of Adolescence, 1999, 22, 657-672.	1.2	60
293	Satisfaction with in-patient psychiatric services. British Journal of Psychiatry, 1999, 174, 159-163.	1.7	109
294	Impact of pregnancy on bulimia nervosa. British Journal of Psychiatry, 1999, 174, 135-140.	1.7	115
295	Incidence and demographic correlates of depressive symptoms during pregnancy in an inner London population. Journal of Psychosomatic Obstetrics and Gynaecology, 1998, 19, 202-209.	1.1	75
296	HIV enteropathy: comparative morphometry of the jejunal mucosa of HIV infected patients resident in the United Kingdom and Uganda. Gut, 1998, 43, 350-355.	6.1	50
297	Disorders of the sleep-wake cycle in adults.. Postgraduate Medical Journal, 1998, 74, 134-138.	0.9	11
298	Smoking and pursuit of thinness in schoolgirls in London and Ottawa. Postgraduate Medical Journal, 1998, 74, 473-479.	0.9	29
299	Changing pattern of drug use in individuals with severe drug dependence following inpatient treatment. International Journal of Psychiatry in Clinical Practice, 1997, 1, 287-294.	1.2	3
300	Subjective sleep-wake parameters in treatment-seeking opiate addicts. Drug and Alcohol Dependence, 1997, 48, 9-16.	1.6	75
301	Quality of statistics in psychiatric research. British Journal of Psychiatry, 1996, 168, 385-385.	1.7	1
302	The incidence and prevalence of anorexia nervosa in three suburban health districts in South West London, U.K.. International Journal of Eating Disorders, 1995, 18, 299-307.	2.1	36
303	HIV infection of human fetal intestinal explant cultures induces epithelial cell proliferation. Aids, 1994, 8, 153-160.	1.0	30
304	Sleep disorders. Consider nocturnal paroxysmal dystonia.. BMJ: British Medical Journal, 1993, 306, 1476-1477.	2.4	1
305	Depletion of neuroendocrine cells in rectal biopsy specimens from HIV positive patients.. Journal of Clinical Pathology, 1992, 45, 524-527.	1.0	4
306	Prospective study of food intake and nutritional status in HIV infection. Journal of Human Nutrition and Dietetics, 1991, 4, 149-154.	1.3	11

#	ARTICLE	IF	CITATIONS
307	Autonomic denervation in jejunal mucosa of homosexual men infected with HIV. <i>Aids</i> , 1991, 5, 1247-1252.	1.0	54
308	Predictors of therapeutic benefit from amitriptyline in mild depression: a general practice placebo-controlled trial. <i>Journal of Affective Disorders</i> , 1988, 14, 83-95.	2.0	281
309	Distress and delay associated with urinary incontinence, frequency, and urgency in women.. <i>BMJ: British Medical Journal</i> , 1988, 297, 1187-1189.	2.4	273
310	Changes in Plasma Concentrations of Leptin and Body Fat Composition during Weight Restoration in Anorexia Nervosa. , 0, .		5